ISEE Description — IVERIC bio Inc
IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases.
|
Free ISEE Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |